<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079376</url>
  </required_header>
  <id_info>
    <org_study_id>MC CP TAN2012-60</org_study_id>
    <nct_id>NCT02079376</nct_id>
  </id_info>
  <brief_title>The DIAMOND® for the Treatment of Type 2 Diabetes</brief_title>
  <official_title>The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metacure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metacure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy of gastric stimulation (GCM) using the DIAMOND System in the
      improvement of glycemic control measured by changes in HbA1c.

      Relationship between blood TG level and the GCM efficacy will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of HbA1c</measure>
    <time_frame>48 weeks</time_frame>
    <description>improvement of glycemic control measured by changes in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between blood TG level and the GCM efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Relationship between blood TG level and the GCM efficacy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Low blood TG patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High blood TG patients treated with blood TG lowering therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with baseline blood triglyceride level &gt; 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High blood TG patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects with baseline blood triglyceride level &gt; 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DIAMOND System</intervention_name>
    <description>DIAMOND Implantable Pulse Generator (IPG)</description>
    <arm_group_label>Low blood TG patients</arm_group_label>
    <arm_group_label>High blood TG patients treated with blood TG lowering therapy</arm_group_label>
    <arm_group_label>High blood TG patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 through 70 years of age

          -  Body mass index &gt; 30 and &lt; 45 (kg/m2)

          -  Type 2 diabetes duration of at least 6 months

          -  Type 2 diabetic subjects treated with oral anti-diabetic agents [Sulfonylurea,
             Metformin, thiazolinedione (TZD) or DPP-4 inhibitors]

          -  Stable anti-diabetic medications for at least 3 months prior to enrollment, six months
             for thiazolinedione (TZD)

          -  The subject has been under routine diabetes care of the investigator or another single
             physician that can supply a medical record for at least 6 months prior to enrollment

          -  HbA1c 7.3% and ≤ 9.5 % on Visit 1

          -  Stable HbA1c, defined as no significant change (variation ≤ 0.5%) between a historical
             value recorded in the subject's medical record within 3 months prior to enrollment and
             the HbA1c gathered on Visit 1.

          -  Fasting blood glucose &gt;120 and &lt; 350 mg/dl on Visit 1.

          -  Women with childbearing potential (i.e., not post-menopausal or surgically sterilized)
             must agree to use adequate birth control methods

          -  Stable weight, defined as no significant weight change (variation &lt;3%) within three
             months prior to enrollment as documented in the subject's medical record. For the
             subject treated with thiazolinedione, stable weight within six months.

          -  If taking theses medication, sable anti-hypertensive and lipid-lowering medication for
             at least one month prior to enrollment

          -  If subject is under anti-depressant medication the treatment needs to be stable for at
             least six months prior to enrollment.

          -  Ability and willingness to perform required study and data collection procedures and
             adhere to operating requirements of the DIAMOND System

          -  Willingness to perform at least four (3) capillary blood glucose tests per day twice a
             week for the duration of the study

          -  Willingness to refrain from using prescription, over the counter or herbal weight loss
             products for the duration of the trial

          -  Alert, mentally competent, and able to understand and willing to comply with the
             requirements of the clinical trial, and personally motivated to abide by the
             requirements and restrictions of the clinical trial

          -  Able to provide voluntary informed consent

        Exclusion Criteria:

          -  Insulin therapy in last 3 months

          -  Taking GLP-1 agonists or in the last 3 months before the enrollment

          -  Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic
             treatment

          -  Subjects with an EF less than 35% or otherwise indicated for an ICD

          -  Taking medications known to affect gastric motility such as narcotics (chronic use)
             and anticholinergics/antispasmodics

          -  Experiencing severe and progressing diabetic complications (i.e. retinopathy not
             stabilized, nephropathy with macroalbuminuria)

          -  Prior wound healing problems due to staphylococcus or candida

          -  Diagnosed with past or current psychiatric condition that may impair his or her
             ability to comply with the study procedures

          -  Use of anti-psychotic medications

          -  Diagnosed with a eating disorder such as bulimia or binge eating

          -  Obesity due to an endocrine disorder (e.g. Cushing disease)

          -  Pregnant or lactating

          -  Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)

          -  Any prior bariatric surgery

          -  Any history of pancreatitis

          -  Any history of peptic ulcer disease within 5 years of enrollment

          -  Diagnosed with gastroparesis

          -  Use of active medical devices (either implantable or external) such as ICD, pacemaker,
             drug infusion device, or neurostimulator (either implanted or worn). Subjects using an
             external active device who are able and willing to avoid use of the device during the
             study may be enrolled.

          -  Cardiac history that physician feels should exclude the subject from the study.

          -  Use of another investigator device or agent in the 30 days prior to enrollment

          -  A history of life-threatening disease within 5 years of enrollment

          -  Change in diabetic medication from between Visit 1 and Visit 3.

          -  Any additional condition(s) that in the Investigator's opinion would warrant exclusion
             from the study or prevent the subject from completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Epworth Research Institute</name>
      <address>
        <city>Richmond, Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spiros Fourlanos, MD</last_name>
      <email>spiros.fourlanos@nh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tilak Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>&quot;Attikon&quot; Hospital</name>
      <address>
        <city>AThens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Evgenidio &quot; Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Arkadopoulos, Prof.</last_name>
      <phone>306937106217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Pineta Grande</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dott. Cristiano Giardiello, MD</last_name>
      <phone>+39335406848</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertrude Mingrone, Prof.</last_name>
      <email>paolo.ferrazza@lnage.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Górska, MD, PhD</last_name>
      <phone>48857468239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Junik, MD, PhD</last_name>
      <phone>48525854020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Diabeta-Care&quot;</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Szykowna, MD, PhD</last_name>
      <phone>48693729109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syrenicz Anhelli, MD, PhD</last_name>
      <phone>4860170884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Postgraduate Medical Education (CMKP)</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiesław Tarnowski, MD, PhD</last_name>
      <phone>+48602346242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika za digestivnu hirurgiju</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miloš BJELOVIĆ, Prof. dr</last_name>
      <email>acerimanovic@hungarotrial.com</email>
    </contact>
    <investigator>
      <last_name>Miloš BJELOVIĆ, Prof. dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut za pluće bolesti Vojvodine</name>
      <address>
        <city>Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslav ILIĆ, Prof. dr</last_name>
      <email>acerimanovic@hungarotrial.com</email>
    </contact>
    <investigator>
      <last_name>Miroslav ILIĆ, Prof. dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

